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Objective: To assess pregnancy levels and patterns of HIV RNA in the absence of antiretroviral
therapy, while appropriately adjusting for potential confounders, including maternal immune
status and race.
Methods: Data on 1 antenatal HIV RNA measurements were available for 333 untreated HIV-
infected pregnant women enrolled in the European Collaborative Study. CD4 counts and HIV RNA
measurements were routinely collected from 1992 and 1998, respectively. Linear mixed effects
models based on 246 women for whom complete data were available examined changes in HIV
RNA levels over pregnancy, with a nested random effects term accounting for measurement
variability within women and period of sample collection.
Results: The change in HIV RNA over pregnancy varied significantly by race ( p = 0.005): from the
second trimester until delivery, HIV RNA decreased significantly by an estimated 0.019 log10
copies/ml/week in white women (95% CI 0.03, 0.007); in black women the estimated 0.016
log10 copies/ml/week increase (95% CI 0.005, 0.037) was not statistically significant. At
delivery, HIV RNA levels in black women were 0.45 log10 copies/ml higher (95% CI 0.08, 0.83)
than in white women.
Conclusions: Our findings suggest that HIV RNA dynamics over pregnancy differ by race, although
other interpretations cannot be excluded, due to potential for unmeasured confounding.
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Pregnancy requires a relative immunosuppression, particu-
larly cell-mediated, to protect the fetus from maternal
rejection.1 This pregnancy-associated decline in cellularPublished by Elsevier Ltd. All rights reserved.
HIV RNA levels in pregnancy 267immune response has also been associated with an increased
frequency of infectious diseases, including viral infections
such as influenza and varicella.2—4 Data available on whether
pregnancy may also impact on HIV RNA levels — the pre-
eminent risk factor for mother-to-child transmission
(MTCT)5,6 — are limited, and may have implications for the
management of HIV-infected pregnant women. Most studies
have reported relatively stable levels during pregnancy,7—11
with some also reporting increases in viral load in the early
postpartum period.7,9 However, these studies included only
small numbers of untreated women, or included women who
were on monotherapy. Additionally these studies either did
not adjust for confounders in adjusted analyses, such as
maternal CD4 counts, or did not use appropriate methods
for repeated measures data.
Using data on over 300 untreated HIV-infected women
enrolled in the European Collaborative Study (ECS), a large
prospective cohort study, this analysis was carried out to
assess pregnancy levels and patterns of HIV RNA viral load in
the absence of antiretroviral therapy, while appropriately
adjusting for potential confounders, including maternal
immune status and race.
Methods
The ECS is an ongoing cohort study established in 1985, in
which HIV-infected pregnant women are enrolled and fol-
lowed in pregnancy and their infants prospectively observed
according to standard protocols.12 Informed consent was
obtained and local ethics committee approval granted. Infor-
mation collected included timing and type of antiretroviral
treatment, maternal CD4 count, HIV RNA viral load, and
socio-demographic characteristics.
CD4 cell counts and HIV RNAviral loadmeasurements were
routinely collected from 1992 and 1998, respectively. Mater-
nal plasma and serum samples for the 263 women delivering
before 1998 were frozen locally and shipped in dry ice to
either of two laboratories in Padua and Stockholm, where
they were stored at 70 8C until testing in 1997/1998, with
the assays used reported; testing of samples for women
delivering post-1998 was performed locally in laboratories
based in tertiary care/university hospitals. For HIV RNA
quantification, the Amplicor HIV-1 monitor tests (standard
and version 1.5, Roche Diagnostic Systems Inc., Branchburg,
NJ, USA), NASBA/Nuclisens assay (Organon Teknika, Oss, the
Netherlands), or Quantiplex HIV-1 RNA (b-DNA) assay (version
3.0; Chiron Diagnostics, Emeryville, CA, USA) were used.
Midpoints were imputed for measurements, which were
recorded at the assay lower limit of quantification.
We restricted the analysis to women who were reported as
untreated prior to and throughout pregnancy, with at least
one HIV RNA measurement during pregnancy. Women receiv-
ing intrapartum only zidovudine for prevention of MTCTwere
not excluded. As women delivered at different gestational
ages, HIV RNA viral load was modeled with respect to weeks
before the time of delivery and therefore ranged from35 to
0 weeks.
Statistical methods
The pattern of log10 transformed HIV RNA viral load over
gestational age was explored using supersmoothers (a runningmean in which the sampling window size varies according to
the local density of measurements); we added a small amount
of random noise to the plot in order to improve data visualiza-
tion. Linear mixed effects (LME) regression models were used
toexamine changes in pregnancy,while adjusting for potential
confounders.13 Change-point, cubic spline, and orthogonal
polynomial models to describe the pattern of HIV RNA over
pregnancy were examined. The most appropriate model was
chosen on the basis of model log-likelihood and Akaike’s
information criteria (AIC); the latter is a goodness of fit
criterion that allows comparison of non-nested models.13,14
The following variables were considered in the model in a
forward stepwise selection procedure and retained if inclusion
resulted in an improved log-likelihood (p  0.10): race (white
or black), first CD4 cell count measured in pregnancy (500,
200—499, or <200 cells/mm3), maternal age (25, 26—31, or
>31 years), time of HIV RNA measurement (weeks before
delivery), type of assay (NASBA/Nuclisens or Roche), blood
material (plasma or serum), timing of HIV diagnosis (before or
during pregnancy), and history of injecting drug use (IDU; yes/
no). The final model included a random effect term for the
intercept nested within the period of sample collection (i.e.,
before and during routine collection of HIV RNAmeasurements
from 1998). Residual plots were used to examine non-normal-
ity of within-group residuals, with a variance power function
added to the final model in an attempt to achieve normality.13
Skewed continuous variables were compared using the Mann—
Whitney test and categorical variables with the Chi-square
test. Analyses were carried out using R version 2.3.115).
Results
The characteristics of the 333 pregnant women with 1 HIV
RNA measurement available are given in Table 1. A fifth of
women were black, with the majority born in sub-Saharan
Africa. Between black and white women there were no
differences in the first CD4 cell count measured (median
460 (IQR 20, 657) cells/mm3 vs. 460 (IQR 70, 550) cells/mm3;
p = 0.18) or in the first HIV RNA measurement (median 3.64
(IQR 3.30, 4.11) log10 copies/ml vs. 3.46 (IQR 3.12, 4.19) log10
copies/ml; p = 0.46), but black women were more likely to
have been diagnosed as HIV-infected during pregnancy (45/
66 vs. 93/247; Chi-square = 15.5; p < 0.0001). The overall
median gestational age at delivery was 38 weeks (IQR 37, 40),
not significantly different for black and white women (med-
ian 38 (IQR 38, 39) vs. 38 (IQR 37, 40); p = 0.67).
Over a third (35%) of women had at least two HIV RNA
measurements, with a median of three measurements per
woman (IQR 3, 4) and the remainder of women had only one
measurement in pregnancy. Nineteen women had measure-
ments taken in the first trimester, 83 in the second trimester,
120 in the third trimester, and 241 at delivery; the median
HIV RNA levels were, respectively, 3.50 (IQR 3.35, 4.01), 3.51
(IQR 3.10, 4.20), 3.52 (IQR 2.70, 4.34), and 2.76 (IQR 2.00,
3.75) log10 copies/ml. The overall proportion of undetectable
HIV RNAmeasurements was high (31%) in this untreated group
of women.
Of the 152 undetectable values of HIV RNA, 13 (9%) were
<50 copies/ml, 91 (60%) were<200 copies/ml, 45 (29%) were
<400 copies/ml and the remaining three (2%) were measured
with detection limits of <500 and <1000 copies/ml. The
proportion of undetectable measurements among samples
Table 1 Baseline characteristics
Characteristic Womena (N = 333) Measurements on womena (N = 490)
Viral load values (copies/ml)
Median (IQR) - 2000 (IQR 350, 11 000)
Viral load measurement
Above detection level - 338 (69)
Below detection level - 152 (31)
First CD4 cell count (cells/mm3)
Median (IQR) 437 (IQR 287, 633) -
Timing of CD4 measurement (weeks from delivery) 13 (IQR 19, 3) -
Missing 45 (14) -
Race
White 249 (77) 356 (76)
Black 66 (21) 101 (21)
Asian 6 (2) 14 (3)
Unknown 12 19
Age at delivery (years)
Median (IQR) 28 (25, 31)
15—26 108 (33) 158 (33)
26—31 140 (43) 198 (41)
32 78 (24) 127 (26)
Unknown 7 7
History of IDU
Non-IDU 156 (49) 248 (53)
IDU 162 (51) 224 (47)
Unknown 15 18
Timing of HIV diagnosis
Pre-pregnancy 182 (55) 287 (59)
Antenatal 151 (45) 203 (41)
HIV RNA assay
NASBA/Nuclisens - 188 (38)
Roche - 283 (58)
Other - 19 (4)
Sampling period
Routine collection 70 (21) 98 (20)
Before routine collection 263 (79) 392 (80)
Year of delivery
1987—1993 228 (68) 350 (71)
1994—1998 40 (12) 52 (11)
1998—2005 65 (20) 88 (18)
IQR, interquartile range; IDU, injecting drug use.
a n (%) unless otherwise stated.
268 European Collaborative Studytaken before 1998 was considerably higher than among those
from the later period (135/392 (34%) vs. 17/98 (17%); Chi-
square = 5.54; p = 0.02), reflecting the lower sensitivity of
the earlier generation of these assays, and almost all of the
later samples were taken from plasma only (data not shown).
HIV RNA levels were measured in plasma for 58% (n = 285) of
samples and were significantly lower than those measured
with serum (median 3.15 (IQR 2.30, 3.95) vs. median 3.48
(IQR 3.00, 4.19), p < 0.001).
Figure 1 reveals the structure of the HIV RNA data
(n = 467) with respect to the time to delivery, with measure-
ments from white and black women marked separately.Overall, there was a slight linear increase until 13 weeks,
followed by a linear decrease up to the time of delivery.
To improve the regression estimates of mean levels of HIV
RNA viral load over pregnancy and to examine interactions
between race and gestational age (only white women had
measurements in early pregnancy), the 23 measurements
available between 35 and 25 weeks (roughly correspond-
ing to 5 and 15 weeks gestation, respectively) and the few
measurements (n = 14) available on Asian women were
excluded leaving 453 measurements. For 86 of the remaining
measurements available, information was missing on at least
one of the variables considered for inclusion in the model; in
Figure 1 Scatter plot of HIV RNA over pregnancy with super-
smoother by race.
HIV RNA levels in pregnancy 269most cases information was missing on CD4 counts (45/86)
and race (19/86). The 367 HIV RNA viral load measurements
included in subsequent LME models were overall similar to
the 100 not included with respect to the distribution of HIV
RNA (median 3.30 (IQR 2.56, 4.08) vs. 3.30 (IQR 2.43, 3.94)
log10 copies/ml; p = 0.41), proportion of censored values
(110/367 (30%) vs. 38/100 (38%); p = 0.16), and crude pattern
of HIV RNA over gestational age (data not shown).
An LME model with a linear term in gestational weeks best
described the pattern of HIV RNA viral load during pregnancy.
Of additional variables considered for inclusion in the model,Table 2 Adjusted coefficients of change for log10 HIV RNA viral l
Multi
HIV RNA at delivery 3.4











WD and race interaction
WD for white women 0.0
WD for black women 0.0
Random effects parameters
s intercept between period of sample collection 0.4
s intercept between women 0.6
CI, confidence interval; IDU, injecting drug use.
a Also adjusted for blood and assay type, with an interaction effectrace, assay, sample type, IDU, and CD4 count were required.
The presence of interaction effects between the linear term
in gestational weeks and race (Chi-square = 7.12; p < 0.01)
and assay and blood sample type (Chi-square = 14.84;
p < 0.001) improved the model fit significantly. An interac-
tion effect between gestational age and CD4 measurements
in pregnancy was not tested, as measurements were taken at
different times for all women and an interaction between IDU
and ethnicity could not be tested as there were no black IDUs.
There was no evidence of an interaction effect between any
other covariates included in the model, including between
CD4 count and ethnicity (Chi-square = 0.35; p = 0.84) or IDU
and time from delivery (Chi-square = 1.73; p = 0.19).
The estimated coefficients of change for mean log10 HIV
RNA viral load and the standard deviations for the random
effect parameters from the final model are given in Table 2.
From around the start of the second trimester (approxi-
mately 13 gestational weeks), HIV RNA viral load was esti-
mated to decrease by 0.019 log10 copies/ml per week up to
delivery for white women. This corresponds to a 4.3% weekly
decrease in HIV RNA copies/ml over pregnancy (95% CI6.7%,
1.6%). The slope of the change in viral load over pregnancy
for black women was positive and significantly different to
that for white women (Table 2); the weekly increase in HIV
RNA viral load over pregnancy for black women was esti-
mated to be 0.016 log10 copies/ml per week (0.005, 0.037),
equating to a 3.8% copies/ml (95% CI 1.1%, 8.9%) weekly
increase, but this was not significantly different from zero,
possibly due to the limited number of measurements andoad in pregnancy
variate coefficienta 95% CI p-Value
1 2.70, 4.12 <0.001
19 0.03, 0.007 0.002
0
5 0.08, 0.83 0.02
0
9 0.05, 0.53 0.02
8 0.44, 1.11 <0.001
0
0 0.47, 0.06 0.14
0
35 0.01, 0.06 0.005
4 0.15, 1.29 -
9 0.60, 0.80 -
between these terms.
270 European Collaborative Studywomen. The intercept estimate in this model corresponds to
the mean HIV RNA level at delivery; the estimated mean at
delivery was 3.41 log10 copies/ml (95% CI 2.70, 3.41) for
white women and 3.86 log10 copies/ml (95% CI 3.16, 4.57) for
black women.
The inclusion of gestational weeks (13—43 weeks gesta-
tion) as the time of HIV RNAmeasurement instead of weeks to
delivery was examined in the final model and resulted in near
identical estimates and standard errors for the mean change
of HIV RNA over pregnancy for white and black women (data
not shown).
In order to estimate the within-woman correlation and to
examine the effect on the regression estimates of excluding
the large number of women who had only one measurement
in pregnancy (65%), a sensitivity analysis including only the 80
womenwith at least two HIV RNAmeasurements in pregnancy
and with available information on all variables was carried
out. The model included the same covariate and interaction
terms as the previous model but without a random effect
term for the sampling period, as its inclusion did not sig-
nificantly improve the model fit here. The mean HIV RNA at
delivery for white women was estimated to be 3.86 log10
copies/ml (95% CI 3.44, 4.28), higher than the 3.41 log10
estimated in the model that included all women, while the
magnitude of the estimated change in HIV RNA over preg-
nancy was smaller, but still statistically significant, at0.013
log10 copies/ml per week (95% CI 0.025, 0.0004). The
between- and within-women standard deviations were esti-
mated to be 0.58 and 0.49, respectively, and the estimated
correlation of log10 HIV RNA within a woman over the 24
weeks of pregnancy observed was 0.66 (95% CI 0.50, 0.79).
Discussion
In this analysis of untreated HIV-infected pregnant women
enrolled within the large ECS mostly before 1997, levels of
HIV RNA did not remain constant over pregnancy. However,
HIV RNA patterns differed significantly by race, with
decreases over gestational age for white women and gen-
erally stable levels for black women. The level of HIV RNA in
pregnancy was also significantly associated with immune
status.
The few studies that have addressed HIV RNA dynamics in
pregnancy in untreated HIV-infected women, have reported
levels to be relatively stable over pregnancy,7,8,10 or
described only small and non-significant decreases in viral
load.9,11,16 However, only two of these five studies used
appropriate statistical methods for correlated longitudinal
data,7,11 and most did not report adjustment for maternal
immune status,8—11,16 which together with HIV RNA levels is
an important prognostic indicator for progression to sympto-
matic disease.17 Here, a linear mixed effects model was
used, which was able to account for variability in measure-
ments within and between women and also allowed for
women with only one measurement to contribute to estima-
tion of the model. The adjusted analysis here included 246
womenwith viral loadmeasurements available from the start
of the second trimester of pregnancy, a larger number of
exclusively untreated women than included in most existing
studies. After adjusting for CD4 count and other covariates
related to viral load, white women were estimated to have a
4.3% weekly decrease in viral load from the start of thesecond trimester up to delivery, while HIV RNA levels for
black women increased over pregnancy, although this was not
statistically significant possibly due to limited sample size.
These results stand in contrast to published studies of
untreated women in pregnancy that report no significant
association between gestation and viral load in untreated
HIV-infected pregnant women, or for those receiving mono
or dual therapy.8—11,16 In a study of 204 women in the Ariel
Project, viral load decreased by a non-significant 2 copies/
ml/day for untreated women or those receiving zidovudine
monotherapy, but rose significantly post-pregnancy.9 An
analysis by the SEROGEST cohort involving 254 pregnant
women, 49% of whom were from sub-Saharan Africa and
without adjustment for CD4 count, revealed no significant
variations during pregnancy, although postpartum values
were significantly lower.8 The statistical methods used,
adjustment for CD4 count and race, and other factors such
as sample size, unobserved population differences, ante-
partum timing of measurements, and the number of
untreated women included in our analysis could explain
why a significant decrease in pregnancy was seen here
and not in any of the other studies examining viral load in
pregnancy.7—11,16
Significant and substantial differences between white
and black women (the latter mostly born in sub-Saharan
Africa) were observed in both levels and patterns of HIV RNA
over pregnancy. In black women, the change in viral load
over pregnancywas estimated to be significantly different to
that of white women, but this increase was not significantly
different to zero. Although there was no significant differ-
ence in the first HIV RNA level observed in pregnancy by
ethnic group, the estimated mean viral load at delivery for
black women was 3.86 log10 copies/ml, significantly higher
than white women who had a mean of 3.41 log10 copies/ml
and is in line with the estimated decrease in white women
and increase in black women over pregnancy. Although
carried out at an earlier time and using qualitative HIV
methods, a virological study carried out in Sweden found
that African women had higher frequencies of positive
plasma isolations than European women, and significantly
so at delivery.18 A different pattern of HIV viral load during
pregnancy among white and black women could possibly be
explained by host biological or genetic differences, or vary-
ing viral characteristics, such as sub-type, between these
groups.
We did not collect data on co-infections during pregnancy,
the presence of which could possibly explain the difference
between white and black women in viral load dynamics in
pregnancy; a recent ECS sub-study analysis of 1050 women
found that women born in Africa were at a significantly
increased risk of having a viral sexually transmitted infection
(STI) diagnosed in pregnancy.19 Concurrent co-infection with
viral STIs, particularly herpes viruses, have been shown to
increase the rate of viral replication, purportedly through
increased levels of certain cytokines or through modulation
of immune responses that control HIV viremia.20 Pregnancy
may be a time of re-activation of chronic viral STI infection
due to relative immunosuppression21 and may help to explain
the finding of a significant difference between black and
white women among viral load levels measured at delivery,
but not at first measurement. Fewer black women in our
study knew their HIV status at the start of pregnancy than
HIV RNA levels in pregnancy 271white women; there is a widespread policy of screening
pregnant women identified as HIV-infected for STIs through-
out Europe,19 but we were unable to assess whether there
was a differential risk of undiagnosed and untreated STI by
ethnic group.
Plasma HIV RNA levels have been reported to be relatively
stable on a week-to-week or month-to-month basis in clini-
cally stable non-pregnant patients, as long as antiretroviral
therapy is not initiated or changed, and a change in viral load
of >0.5 log10 is generally considered to reflect a biologically
relevant change in the level of viral replication.22 Addition-
ally, hemodilution occurring in pregnancy results in increases
in plasma volume of up to 50%, with most of the increase
occurring after the first trimester23 and complicates the
interpretation of measurements of immune markers in preg-
nancy, including lymphocytes, with declining values over
pregnancy associated with hemodilution.24—26 In this analy-
sis, mean HIV RNA levels in white women were estimated to
decrease by approximately 0.46 log10 copies/ml in the 24
weeks of follow-up over the second and third trimesters of
pregnancy; this equates to an approximate decrease of 65%
and may be explained by changes in plasma volume in
pregnancy and intra-assay sample and biologic variability
alone.
Several study limitations should be acknowledged when
interpreting these results. As our objective was to model
HIV RNA patterns in pregnancy in untreated women, most
(80%) viral load measurements were from women enrolled
in the earlier years of the ECS, when such measurements
were not routinely collected. In this period, availability of
viral load and CD4 measurements was dependent on the
individual center and therefore, although representative of
the HIV-infected population in each center, the extent to
which these women are representative of other untreated
pregnant women in the ECS during the same period is
unknown. The number of undetectable HIV RNA measure-
ments (152; 31%) among this untreated group of women was
also high, and the proportion of undetectable measure-
ments among samples taken before 1998, where some had
been stored for a longer duration, was considerably higher
than among those from the later period. These early HIV
RNA measurements were obtained from serum and plasma
samples (stored at 70 8C) for several years and the extent
of the effect of duration of storage on the accuracy of
quantification of test results is uncertain.27,28 The analyses
were adjusted for sample and assay type and a nested
random effects structure was used to account for any
unobserved differences between measurements taken from
this earlier time period, which should have reduced some of
the bias in the estimates from these models. However we
were unable to adjust for the lower sensitivity of earlier
generations of assays, which partly explains the finding of a
large number of undetectable measurements in the earlier
period of the study and the results here should be inter-
preted in this light. The large number of women with only
one measurement may also limit inferences on the shape of
viral load over pregnancy; however a sensitivity analysis
including women with at least two measurements also
revealed a decreasing slope in pregnancy for white women,
albeit of smaller magnitude.
In summary, we found a significant association between
HIV RNA levels and maternal immune status in HIV-infectedwomen who remained untreated throughout pregnancy, with
significant race-specific variations in viral load with increas-
ing gestation. Although we acknowledge possible limitations
of our study, the proven success of antiretroviral therapy
means that it is unlikely that additional data on untreated
pregnant women will become available and our findings may
thus be among the last to shed light on the complicated
relationship between pregnancy and virological markers of
HIV infection.
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